版本:
中国

BRIEF-Alfataliglicerase approved for pediatric indications in Brazil for the treatment of gaucher disease in children four years and older

Nov 22 Protalix Biotherapeutics Inc :

* Alfataliglicerase approved for pediatric indications in brazil for the treatment of gaucher disease in children four years and older

* Brazilian National Health Surveillance Agency (bnhsa) has granted regulatory approval for Alfataliglicerase

* Protalix Biotherapeutics-Alfataliglicerase approved as long-term enzyme replacement therapy for children 4 years old & above with type i gaucher disease Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐